Updates are available Correction dated 2025-07-17
Click to view Correction: https://doi.org/10.1186/s12348-025-00513-6
-
Authors
Shields, Melissa K.
Ferreira, Lisia Barros
Ali, Syed B.
Dedina, Liana
Lim, Lyndell L.
Suhler, Eric B.
Smith, Justine R.
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (2022548, 2025222)
- License Information
-
More Information
Article History
Received: 19 March 2025
Accepted: 10 May 2025
First Online: 5 June 2025
Change Date: 17 July 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12348-025-00513-6
Declarations
:
: Not applicable.
: Not applicable.
: Melissa K. Shields: Declaring no competing interests. Lisia Barros Ferreira: Declaring no competing interests. Syed B. Ali: Declaring no competing interests. Liana Dedina: Declaring no competing interests. Lyndell L. Lim: Allergan (consultant), Abbvie, Inc. (consultant), Bayer (consultant and research funding to the institution), Novartis (consultant), Roche (consultant and research funding to the institution), and Novotech (consultant). Eric B. Suhler: Abbvie, Acelyrin, Aldeyra, Alimera (formerly pSivida, EyePoint), Alumis, Bausch and Lomb, Bristol Myers Squibb, Centocor, Clearside, Genentech, Gilead, Kriya, Merck, Novartis, Roche (consultant for all); and Abbvie, Acelyrin, Aldeyra, Alimera, Bausch and Lomb, Bristol Myers Squibb, Centocor, Clearside, Genentech, Gilead, Novartis, Roche, Department of Veterans Affairs, Research to Prevent Blindness (research support for all). Justine R. Smith: Abbvie (consultant), Allergan (consultant), Abbott Immunology (consultant), Bausch and Lomb Pharmaceuticals (clinical trial sponsorship), and Centocor (clinical trial sponsorship).
